Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H4Z3
UPID:
CAPAM_HUMAN
Alternative names:
Cap-specific adenosine methyltransferase; Phosphorylated CTD-interacting factor 1; Protein phosphatase 1 regulatory subunit 121
Alternative UPACC:
Q9H4Z3; E1P5P1; Q54AB9; Q9NT85
Background:
The mRNA (2'-O-methyladenosine-N(6)-)-methyltransferase, also known as Cap-specific adenosine methyltransferase, plays a pivotal role in mRNA processing. It catalyzes the formation of N(6),2'-O-dimethyladenosine cap (m6A(m)) on the second transcribed position of capped mRNAs. This enzyme is integral to the early elongation complex of RNA polymerase II, highlighting its essential function in gene expression regulation.
Therapeutic significance:
Understanding the role of mRNA (2'-O-methyladenosine-N(6)-)-methyltransferase could open doors to potential therapeutic strategies. Its critical function in mRNA processing and gene expression regulation makes it a promising target for drug discovery, offering new avenues for treating diseases at the genetic and molecular levels.